knowledge -WSS

knowledge

author：focus 2025-09-06 04:30:32 - browse：71

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Sana to lay off nearly a third of staff, de

WSS

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

UCLA team creates talking throat patch for voice disorders

When women are denied an abortion, their children fare worse than peers

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

hotspot

knowledge

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

In age of alternative facts, a scholarly course on calling out crap

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

State Dept. review finds Biden bears some blame for Afghanistan failures

A Q&A with the global head of Boehringer Ingelheim's innovation unit

At least 13 dead in Texas as scorching temps continue

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Medicare details structure of new drug price negotiation program

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

focus

Steward Health Care Massachusetts hospitals face fiscal disaster

As AI in medicine takes off, can 'human in the loop' prevent harm?

WuXi out of biotech trade group, U.S. and China relations to blame

Readout Newsletter: Bristol, Sangamo, Gilead, and more

How many hemophilia patients actually want gene therapy?

John Green on his newest strategy for fighting tuberculosis

hotspot

focus

entertainment

focus